53 related articles for article (PubMed ID: 16434383)
1. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
Offidani M; Corvatta L; Marconi M; Visani G; Alesiani F; Brunori M; Galieni P; Catarini M; Burattini M; Centurioni R; Rupoli S; Scortechini AR; Giuliodori L; Candela M; Capelli D; Montanari M; Olivieri A; Piersantelli MN; Leoni P
Haematologica; 2006 Jan; 91(1):133-6. PubMed ID: 16434383
[TBL] [Abstract][Full Text] [Related]
2. Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
Papanikolaou X; Szymonifka J; Rosenthal A; Heuck CJ; Mitchell A; Johann D; Keller J; Waheed S; Usmani SZ; Van Rhee F; Bailey C; Petty N; Hoering A; Crowley J; Barlogie B
Haematologica; 2013 Jul; 98(7):1147-53. PubMed ID: 23716540
[TBL] [Abstract][Full Text] [Related]
3. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Barlogie B; van Rhee F; Shaughnessy JD; Epstein J; Yaccoby S; Pineda-Roman M; Hollmig K; Alsayed Y; Hoering A; Szymonifka J; Anaissie E; Petty N; Kumar NS; Srivastava G; Jenkins B; Crowley J; Zeldis JB
Blood; 2008 Oct; 112(8):3122-5. PubMed ID: 18669874
[TBL] [Abstract][Full Text] [Related]
4. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Palumbo A; Bringhen S; Caravita T; Merla E; Capparella V; Callea V; Cangialosi C; Grasso M; Rossini F; Galli M; Catalano L; Zamagni E; Petrucci MT; De Stefano V; Ceccarelli M; Ambrosini MT; Avonto I; Falco P; Ciccone G; Liberati AM; Musto P; Boccadoro M;
Lancet; 2006 Mar; 367(9513):825-31. PubMed ID: 16530576
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
6. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Garderet L; Iacobelli S; Moreau P; Dib M; Lafon I; Niederwieser D; Masszi T; Fontan J; Michallet M; Gratwohl A; Milone G; Doyen C; Pegourie B; Hajek R; Casassus P; Kolb B; Chaleteix C; Hertenstein B; Onida F; Ludwig H; Ketterer N; Koenecke C; van Os M; Mohty M; Cakana A; Gorin NC; de Witte T; Harousseau JL; Morris C; Gahrton G
J Clin Oncol; 2012 Jul; 30(20):2475-82. PubMed ID: 22585692
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
Kropff M; Baylon HG; Hillengass J; Robak T; Hajek R; Liebisch P; Goranov S; Hulin C; Bladé J; Caravita T; Avet-Loiseau H; Moehler TM; Pattou C; Lucy L; Kueenburg E; Glasmacher A; Zerbib R; Facon T
Haematologica; 2012 May; 97(5):784-91. PubMed ID: 22133776
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.
Offidani M; Corvatta L; Piersantelli MN; Visani G; Alesiani F; Brunori M; Galieni P; Catarini M; Burattini M; Centurioni R; Ferranti M; Rupoli S; Scortechini AR; Giuliodori L; Candela M; Capelli D; Montanari M; Olivieri A; Poloni A; Polloni C; Marconi M; Leoni P
Blood; 2006 Oct; 108(7):2159-64. PubMed ID: 16763209
[TBL] [Abstract][Full Text] [Related]
9. What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma.
Costa BA; Mouhieddine TH; Richter J
Target Oncol; 2022 Jul; 17(4):383-405. PubMed ID: 35771402
[TBL] [Abstract][Full Text] [Related]
10. Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients.
Ria R; Melaccio A; Racanelli V; Vacca A
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32517267
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.
Patel VG; Cornell RF
Curr Oncol Rep; 2019 Mar; 21(4):29. PubMed ID: 30834998
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Holstein SA; McCarthy PL
Drugs; 2017 Apr; 77(5):505-520. PubMed ID: 28205024
[TBL] [Abstract][Full Text] [Related]
13. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.
Laubach J; Garderet L; Mahindra A; Gahrton G; Caers J; Sezer O; Voorhees P; Leleu X; Johnsen HE; Streetly M; Jurczyszyn A; Ludwig H; Mellqvist UH; Chng WJ; Pilarski L; Einsele H; Hou J; Turesson I; Zamagni E; Chim CS; Mazumder A; Westin J; Lu J; Reiman T; Kristinsson S; Joshua D; Roussel M; O'Gorman P; Terpos E; McCarthy P; Dimopoulos M; Moreau P; Orlowski RZ; Miguel JS; Anderson KC; Palumbo A; Kumar S; Rajkumar V; Durie B; Richardson PG
Leukemia; 2016 May; 30(5):1005-17. PubMed ID: 26710887
[TBL] [Abstract][Full Text] [Related]
14. Novel agents and new therapeutic approaches for treatment of multiple myeloma.
Ria R; Reale A; Vacca A
World J Methodol; 2014 Jun; 4(2):73-90. PubMed ID: 25332907
[TBL] [Abstract][Full Text] [Related]
15. Cancer cell spheroids as a model to evaluate chemotherapy protocols.
Perche F; Torchilin VP
Cancer Biol Ther; 2012 Oct; 13(12):1205-13. PubMed ID: 22892843
[TBL] [Abstract][Full Text] [Related]
16. Is there a role for 'modified VAD' in the treatment of multiple myeloma?
Agazzi A; Sammassimo S; Laszlo D; Liptrott S; Cascio R; Alietti A; Rabascio C; Mancuso P; Pruneri G; Martinelli G
Ecancermedicalscience; 2009; 3():136. PubMed ID: 22276003
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed and refractory myeloma.
Kaufman J; Gleason C; Lonial S
Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421
[TBL] [Abstract][Full Text] [Related]
18. Advances in treatment for relapses and refractory multiple myeloma.
Richards T; Weber D
Med Oncol; 2010 Jun; 27 Suppl 1():S25-42. PubMed ID: 20213220
[TBL] [Abstract][Full Text] [Related]
19. The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Laubach JP; Mahindra A; Mitsiades CS; Schlossman RL; Munshi NC; Ghobrial IM; Carreau N; Hideshima T; Anderson KC; Richardson PG
Leukemia; 2009 Dec; 23(12):2222-32. PubMed ID: 19741729
[TBL] [Abstract][Full Text] [Related]
20. Front line treatment of elderly multiple myeloma in the era of novel agents.
Venon MD; Roccaro AM; Gay J; Moreau AS; Dulery R; Facon T; Ghobrial IM; Leleu X
Biologics; 2009; 3():99-109. PubMed ID: 19707399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
